Document Type : Original Article(s)
- Seyed Mohammad Hashemi Jazi 1
- Mohammad Hossein Nasr Esfahani 2
- Mehrafarin Fesharaki 3
- Fariba Moulavi 4
- Mojgan Gharipour 5
1 Associate Professor, School of Medicine, Isfahan University Of Medical Sciences, Isfahan, Iran
2 PhD, Cell Sciences Research Center, Royan Institute for Stem Cell Biology and Technology, Avicenna Research Institute (ACECR), Tehran, Iran.
3 MSc, Department of Cell Sciences Research Center Medical Sciences, School of Medicine, Isfahan University of Medical Sciences
4 BSc, Cell Sciences Research Center, Royan Institute for Stem Cell Biology and Technology, Avicenna Research Institute (ACECR), Tehran, Iran
5 MSc Researcher, Cardiac Rehabilitation Research Center, Isfahan Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran.
BACKGROUND: Myocardial infarction (MI) is an irreversible cardiomyocytes injury which begins after 15-20 minutes of coronary artery occlusion. The extent of infarction is modulated by a number of factors including collateral blood supplies, medications, and ischemic preconditioning. Although angioplasty and thrombolytic agents can relieve the cause of the infarction, the time from the occlusion onset to reperfusion determines the degree of irreversible myocardial injury. Experimental studies suggested that stem cells and progenitor cells derived from bone marrow can be used in the repair of cardiac tissue after acute MI. This study was designed to investigate the feasibility, safety and initial clinical outcome of intracoronary infusion of autologous progenitor cells in patients with acute MI.METHODS: Patients with a history of anterior MI and a left ventricular ejection fraction (LVEF) less than 35 % who were candidates for coronary angioplasty were randomly allocated in a 1:1 ratio to either control or bone marrow cell groups (each including 16 patients). Thallium scan and 17-segment echocardiography analysis for regional wall motion abnormality were performed before and 1 and 6 months after intracoronary infusion of bone marrow cells. The same tests were also conducted for the control group at identical time intervals. Categorical variables were compared by one way analysis of variance (ANOVA). Statistical significance was assumed at a value of P < 0.05.RESULTS: LVEF in the case and control groups increased to 39.37 ± 24.7% and 31.00 ± 1.87%, respectively (P = 0.069 and 0.1, respectively). Wall motion abnormality index (WMAI) decreased insignificantly in both groups. Perfusion defect scores (PDSs) decreased significantly in the case group.CONCLUSION: In this study, autologous mesenchymal stem cell transplantation by intracoronary catheter during angioplasty in patients with a history of severe LV dysfunction caused mild increases in LVEF.Keywords: Myocardial Infarction Left Ventricular Failure, Stem Cell.